Oculis Holding AG

OCS · NASDAQ

$7.49+$0.17 (+2.32%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.32

About OCS

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Employees: 60
Headquarters: Zug, Zug
Listed: Mar 3, 2023
Sector: Health Care
Industry: Pharmaceuticals
Website: oculis.com

Leadership

Oculis Holding AG executives
Name	Title	Since	Age
Anthony Rosenberg	—	—	72
Riad Sherif	—	2017	57
Sylvia Cheung	—	—	50
Pall Johannesson	—	2024	44
Katie Kazem	—	—	—
Christina Ackermann	—	—	60
Lionel Carnot	—	—	57
Arshad Khanani	—	—	46
Martijn Kleijwegt	—	2023	70
Geraldine O'Keeffe	—	—	59
Robert Warner	—	—	58

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.